BeOne Medicines Q2 Revenue Hits $1.7B, Raises 2026 Guidance
ONC sits 30% above its 52-week low of $253.948.
Summary
BeOne Medicines delivered a strong Q2 with total revenue of $1.7 billion, up 30% year-over-year, driven by its flagship BRUKINSA which grew 31% to $1.2 billion. GAAP diluted EPS came in at $2.05, while non-GAAP diluted EPS reached $3.84, both significantly above prior-year levels. Management raised full-year 2026 revenue guidance to $6.6-$6.8 billion and now expects GAAP operating income of $1-$1.1 billion. This follows the recent FDA accelerated approval for BEQALZI in May and a pattern of insider selling by the CEO under 10b5-1 plans. The raised guidance and robust product sales reinforce the company's commercial momentum in oncology.
At the time of this announcement, ONC was trading at $329.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.9B. The 52-week trading range was $253.95 to $385.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.